Research Progress of SN38 Drug Delivery System in Cancer Treatment

The active metabolite of irinotecan (CPT-11), 7-ethyl-10-hydroxycamptothecin (SN38), is 100-1000 times more active than CPT-11 and has shown inhibitory effects on a range of cancer cells, including those from the rectal, small cell lung, breast, esophageal, uterine, and ovarian malignancies. Despite...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of nanomedicine Vol. 19; pp. 945 - 964
Main Authors Qi, Qing-Rui, Tian, Huan, Yue, Bao-Sen, Zhai, Bing-Tao, Zhao, Feng
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2024
Dove
Dove Medical Press
Subjects
Amino acids
Biological products
Camptothecin
Cancer
Cell Line, Tumor
Complications and side effects
drug delivery system
Drug Delivery Systems
Drugs
Irinotecan - therapeutic use
Liposomes - therapeutic use
Metabolites
Micelles
Nanoparticles - chemistry
Neoplasms - drug therapy
Oncology, Experimental
Review
sn38
Vehicles
SN38
cancer
drug delivery system
Online AccessGet full text

Cover

More Information
Summary:The active metabolite of irinotecan (CPT-11), 7-ethyl-10-hydroxycamptothecin (SN38), is 100-1000 times more active than CPT-11 and has shown inhibitory effects on a range of cancer cells, including those from the rectal, small cell lung, breast, esophageal, uterine, and ovarian malignancies. Despite SN38's potent anticancer properties, its hydrophobicity and pH instability have caused substantial side effects and anticancer activity loss, which make it difficult to use in clinical settings. To solve the above problems, the construction of SN38-based drug delivery systems is one of the most feasible methods to improve drug solubility, enhance drug stability, increase drug targeting ability, improve drug bioavailability, enhance therapeutic efficacy and reduce adverse drug reactions. Therefore, based on the targeting mechanism of drug delivery systems, this paper reviews SN38 drug delivery systems, including polymeric micelles, liposomal nanoparticles, polymeric nanoparticles, protein nanoparticles, conjugated drug delivery systems targeted by aptamers and ligands, antibody-drug couplings, magnetic targeting, photosensitive targeting, redox-sensitive and multi-stimulus-responsive drug delivery systems, and co-loaded drug delivery systems. The focus of this review is on nanocarrier-based SN38 drug delivery systems. We hope to provide a reference for the clinical translation and application of novel SN38 medications.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1178-2013
1176-9114
1178-2013
DOI:10.2147/IJN.S435407